SARS-CoV-2 Omicron Variant is Expected to Retain Most of the Spike Protein Specific Dominant T-Cell Epitopes Presented by COVID-19 Vaccines—Worldwide,2021  

作　　者：Jiajing Jiang Yingying Du Tao Peng 

机构地区：[1]State Key Laboratory of Respiratory Disease,Sino-French Hoffmann Institute,College of Basic Medical Science,Guangzhou Medical University,Guangzhou,Guangdong,China [2]Guangdong South China Vaccine,Guangzhou,Guangdong,China

出　　处：《China CDC weekly》2022年第18期381-384,共4页中国疾病预防控制中心周报（英文）

基　　金：Guangzhou Science and Technology Innovation Committee(CYLJTD-201602);the Guangzhou Institute of Respiratory Health Open Project(Funds Provided by China Evergrande Group:2020GIRHHMS20);the Guangzhou Laboratory(EKPG21-26);the Science,Technology,and Information Bureau of Guangzhou Development District(2018-L08).

摘　　要：Summary What is already known about this topic?The newly emerged variant of Omicron,which carries many of the mutations found in other variants of concern(VOCs),as well as a great number of new mutations that may enhance its immune escape,has spread rapidly around the world.This has raised public concern about the effectiveness of the current coronavirus disease 2019(COVID-19)vaccine.What is added by this report?In this study,different bioinformatic softwares were applied to predict the dominant Omicron spike(S)protein cytotoxic T lymphocyte(CTL)and T helper(Th)epitopes in representative world population and Chinese population.Compared to the original severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)S protein,limited mutations were identified within the dominant CTL and Th epitopes in Omicron variant.What are the implications for public health practice?The results of this study suggested that the current COVID-19 vaccine-induced T-cell immunity may still provide significant protection against Omicron variant infection in fully vaccinated individuals.

关 键 词：vaccine immunity raised 

分 类 号：R37[医药卫生—病原生物学] R51[医药卫生—基础医学]